Results 21 to 30 of about 12,137 (255)

The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder

Translational Psychiatry, 2022
Bumetanide, a drug being studied in autism spectrum disorder (ASD) may act to restore gamma-aminobutyric acid (GABA) function, which may be modulated by the immune system. However, the interaction between bumetanide and the immune system remains unclear.
Qingyang Li, Lingli Zhang, Haidi Shan, Juehua Yu, Yuan Dai, Hua He, Wei-Guang Li, Christelle Langley, Barbara J. Sahakian, Yin Yao, Qiang Luo, Fei Li   +11 more
doaj   +1 more source

Dose Response of Bumetanide on Aquaporins and Angiogenesis Biomarkers in Human Retinal Endothelial Cells Exposed to Intermittent Hypoxia

Pharmaceuticals, 2021
Aquaporins (AQPs) are important for regulating cellular water, solute transport, and balance. Recently, AQPs have also been recognized as playing a key role in cell migration and angiogenesis.
Sibel Guzel, Charles L. Cai, Jacob V. Aranda, Kay D. Beharry   +3 more
doaj   +1 more source

Bumetanide

, 2006
europepmc   +2 more sources

Bumetanide attenuates sevoflurane‐induced neuroapoptosis in the developing dentate gyrus and impaired behavior in the contextual fear discrimination learning test

Brain and Behavior, 2022
Introduction Sevoflurane acts as a gamma‐aminobutyric acid subtype A receptor agonist and can induce widespread apoptosis of immature dentate granule cells in postnatal day 21 mice.
Kai Wei, Yiheng Liu, Xiamin Yang, Jin Liu, Yuan Li, Meng Deng, Yingwei Wang   +6 more
doaj   +1 more source

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis [PDF]

, 2017
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure.
De Vecchis, Ferrannini, Fitchett, Francis, Greenberg, Hammon, Heise, Heise, Hirose, Lindner, Neal, Peacock, Rabe, Schmieder, Schneider, Schrier, Schrier, Shimizu, Titze, Titze, Titze, Weinfeld, Zinman   +22 more
core   +1 more source

Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundDapagliflozin inhibits the sodium‐glucose–linked transporter 2 in the renal proximal tubule, thereby promoting glycosuria to reduce hyperglycemia in type 2 diabetes mellitus. Because these patients may require loop diuretics, and sodium‐glucose–
Christopher S. Wilcox, Wen Shen, David W. Boulton, Bruce R. Leslie, Steven C. Griffen   +4 more
doaj   +1 more source

Sodium chloride transport of normal and dietary enlarged rat cecum in vitro [PDF]

, 1998
Sodium chloride transport across isolated cecum mucosa was investigated in normal rats and rats with adaptive cecum growth induced by dietary polyethylene glycol (PEG). The normal cecum absorbed CI in excess of Na with a small short-circuit current (Isc).
Loeschke, Klaus, Schreiner, Josefine, Weber, Matthias   +2 more
core   +1 more source

Inhibition of NKCC1 Modulates Alveolar Fluid Clearance and Inflammation in Ischemia-Reperfusion Lung Injury via TRAF6-Mediated Pathways

Frontiers in Immunology, 2018
Background: The expression of Na-K-2Cl cotransporter 1 (NKCC1) in the alveolar epithelium is responsible for fluid homeostasis in acute lung injury (ALI). Increasing evidence suggests that NKCC1 is associated with inflammation in ALI.
Chih-Hao Shen, Chih-Hao Shen, Chih-Hao Shen, Jr-Yu Lin, Yung-Lung Chang, Shu-Yu Wu, Chung-Kan Peng, Chin-Pyng Wu, Kun-Lun Huang, Kun-Lun Huang   +9 more
doaj   +1 more source

Beta-Amyloid (Aβ_1-42) Increases the Expression of NKCC1 in the Mouse Hippocampus

Molecules, 2022
Alzheimer’s disease (AD) is a neurodegenerative disorder with an increasing need for developing disease-modifying treatments as current therapies only provide marginal symptomatic relief.
Patricia Lam, Chitra Vinnakota, Beatriz Calvo-Flores Guzmán, Julia Newland, Katie Peppercorn, Warren P. Tate, Henry J. Waldvogel, Richard L. M. Faull, Andrea Kwakowsky   +8 more
doaj   +1 more source

A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders

Cells, 2022
The specific NKCC1 cotransporter antagonist, bumetanide, attenuates the severity of Autism Spectrum Disorders (ASD), and many neurodevelopmental or neurodegenerative disorders in animal models and clinical trials.
Eric Delpire, Yehezkel Ben-Ari
doaj   +1 more source